Compare GDOT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | RGNX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.3M | 661.2M |
| IPO Year | 2010 | 2015 |
| Metric | GDOT | RGNX |
|---|---|---|
| Price | $13.00 | $12.22 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $11.00 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 1.2M | 586.6K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,007,128,000.00 | $161,318,000.00 |
| Revenue This Year | $22.03 | $198.02 |
| Revenue Next Year | $11.64 | $2.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.16 | ★ 91.30 |
| 52 Week Low | $6.13 | $5.04 |
| 52 Week High | $15.41 | $13.93 |
| Indicator | GDOT | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 52.03 |
| Support Level | $10.42 | $10.76 |
| Resistance Level | $12.64 | $13.80 |
| Average True Range (ATR) | 0.56 | 0.79 |
| MACD | 0.26 | 0.10 |
| Stochastic Oscillator | 98.29 | 47.58 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.